Palo Capital Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 2.3% during the 4th quarter, Holdings Channel reports. The firm owned 50,217 shares of the biopharmaceutical company’s stock after purchasing an additional 1,130 shares during the period. Palo Capital Inc.’s holdings in Pfizer were worth $2,192,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Carnick & Kubik Group LLC raised its position in shares of Pfizer by 14.0% in the 4th quarter. Carnick & Kubik Group LLC now owns 164,657 shares of the biopharmaceutical company’s stock valued at $7,187,000 after acquiring an additional 20,159 shares during the period. Old Port Advisors acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $3,801,000. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC raised its position in shares of Pfizer by 36.6% in the 4th quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC now owns 14,939 shares of the biopharmaceutical company’s stock valued at $652,000 after acquiring an additional 4,006 shares during the period. Cedar Capital LLC raised its position in shares of Pfizer by 7.9% in the 4th quarter. Cedar Capital LLC now owns 14,125 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 1,038 shares during the period. Finally, Valeo Financial Advisors LLC raised its position in shares of Pfizer by 0.5% in the 4th quarter. Valeo Financial Advisors LLC now owns 114,331 shares of the biopharmaceutical company’s stock valued at $4,991,000 after acquiring an additional 593 shares during the period. 69.36% of the stock is currently owned by institutional investors.
Shares of PFE stock opened at $40.66 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.33 and a current ratio of 1.57. The company has a market cap of $241.92 billion, a price-to-earnings ratio of 13.55, a P/E/G ratio of 2.35 and a beta of 0.71. Pfizer Inc. has a 52 week low of $35.32 and a 52 week high of $46.47.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 10th will be issued a dividend of $0.36 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.44 annualized dividend and a yield of 3.54%. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.
In related news, major shareholder Pfizer Inc bought 50,000 shares of the company’s stock in a transaction on Monday, May 13th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $850,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mikael Dolsten sold 149,553 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $43.55, for a total transaction of $6,513,033.15. Following the sale, the insider now owns 390,097 shares in the company, valued at $16,988,724.35. The disclosure for this sale can be found here. Insiders have sold a total of 288,726 shares of company stock worth $12,534,617 over the last 90 days. Corporate insiders own 0.09% of the company’s stock.
A number of brokerages recently weighed in on PFE. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research report on Thursday, January 31st. Zacks Investment Research downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a research report on Friday, January 25th. Credit Suisse Group reiterated a “buy” rating and issued a $48.00 price target on shares of Pfizer in a research report on Monday, May 6th. Barclays reiterated a “hold” rating and issued a $41.00 price target on shares of Pfizer in a research report on Thursday, May 9th. Finally, Bank of America increased their price target on shares of Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research report on Monday, April 1st. Fourteen analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $45.83.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/15/palo-capital-inc-acquires-1130-shares-of-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: Why is momentum important to successful trading?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.